An implementation research programme to support an intravenous iron intervention for pregnant women with moderate and severe anaemia in Malawi: study protocol.

Anaemia Implementation research Intravenous iron Low- and middle-income countries Malawi Maternal health

Journal

Implementation science communications
ISSN: 2662-2211
Titre abrégé: Implement Sci Commun
Pays: England
ID NLM: 101764360

Informations de publication

Date de publication:
21 Jun 2022
Historique:
received: 11 04 2022
accepted: 24 04 2022
entrez: 21 6 2022
pubmed: 22 6 2022
medline: 22 6 2022
Statut: epublish

Résumé

Antenatal iron supplementation is critical to maternal and child health; however, access and adherence to oral iron are inconsistent in many low- and middle-income countries (LMICs). Modern intravenous (IV) iron products have become available in high-income clinical settings and provide an opportunity to deliver high doses of iron in a single-short infusion during pregnancy. However, there is limited knowledge of the drivers and barriers for such an intervention to be effectively delivered and upscaled in LMICs. In this study protocol, we describe the implementation research programme to support an IV iron intervention in Malawi for pregnant women with moderate and severe anaemia. The implementation research programme has three phases, each guided by implementation science conceptual frameworks. In Phase 1, we will conduct formative research (context assessment of the health system with key informant interviews) to determine how IV iron can be effectively introduced into routine antenatal care. We will use the findings to co-develop potential strategies with end-users and healthcare providers to improve intervention implementation. In Phase 2, we will disseminate the implementation strategies to support the uptake and delivery of the intervention in the study settings. In Phase 3, the intervention will be implemented, and we will conduct formative evaluation (interviews with end-users, healthcare providers, and analysis of health services data) to investigate the feasibility and acceptability of the intervention and strategies. We will also identify processes and contextual factors that facilitate or impede the delivery and uptake of IV iron. In LMICs, modern IV iron products present a novel opportunity to rapidly cure moderate and severe anaemia in pregnancy, thereby improving maternal and child health outcomes. This implementation research programme will provide guidance and recommendations on how best an IV iron intervention for pregnant women with anaemia can be implemented in an LMIC setting like Malawi. We will develop locally relevant and culturally appropriate implementation strategies by engaging with key stakeholders (pregnant women, healthcare providers, and policymakers) and identifying factors likely to facilitate successful implementation. The findings of this research can guide the implementation of an IV iron intervention in Malawi and other LMICs.

Sections du résumé

BACKGROUND BACKGROUND
Antenatal iron supplementation is critical to maternal and child health; however, access and adherence to oral iron are inconsistent in many low- and middle-income countries (LMICs). Modern intravenous (IV) iron products have become available in high-income clinical settings and provide an opportunity to deliver high doses of iron in a single-short infusion during pregnancy. However, there is limited knowledge of the drivers and barriers for such an intervention to be effectively delivered and upscaled in LMICs. In this study protocol, we describe the implementation research programme to support an IV iron intervention in Malawi for pregnant women with moderate and severe anaemia.
METHODS METHODS
The implementation research programme has three phases, each guided by implementation science conceptual frameworks. In Phase 1, we will conduct formative research (context assessment of the health system with key informant interviews) to determine how IV iron can be effectively introduced into routine antenatal care. We will use the findings to co-develop potential strategies with end-users and healthcare providers to improve intervention implementation. In Phase 2, we will disseminate the implementation strategies to support the uptake and delivery of the intervention in the study settings. In Phase 3, the intervention will be implemented, and we will conduct formative evaluation (interviews with end-users, healthcare providers, and analysis of health services data) to investigate the feasibility and acceptability of the intervention and strategies. We will also identify processes and contextual factors that facilitate or impede the delivery and uptake of IV iron.
DISCUSSION CONCLUSIONS
In LMICs, modern IV iron products present a novel opportunity to rapidly cure moderate and severe anaemia in pregnancy, thereby improving maternal and child health outcomes. This implementation research programme will provide guidance and recommendations on how best an IV iron intervention for pregnant women with anaemia can be implemented in an LMIC setting like Malawi. We will develop locally relevant and culturally appropriate implementation strategies by engaging with key stakeholders (pregnant women, healthcare providers, and policymakers) and identifying factors likely to facilitate successful implementation. The findings of this research can guide the implementation of an IV iron intervention in Malawi and other LMICs.

Identifiants

pubmed: 35729604
doi: 10.1186/s43058-022-00299-x
pii: 10.1186/s43058-022-00299-x
pmc: PMC9210048
doi:

Types de publication

Journal Article

Langues

eng

Pagination

68

Subventions

Organisme : Bill and Melinda Gates Foundation
ID : INV 004505

Informations de copyright

© 2022. The Author(s).

Références

Obstet Gynecol. 2007 Aug;110(2 Pt 1):267-78
pubmed: 17666600
BMJ Qual Saf. 2020 Jan;29(1):64-76
pubmed: 31548278
Lancet. 2021 Jan 16;397(10270):233-248
pubmed: 33285139
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Wellcome Open Res. 2018 Nov 1;3:141
pubmed: 30662959
Reprod Health. 2018 Jun 22;15(Suppl 1):96
pubmed: 29945649
Lancet Glob Health. 2016 Mar;4(3):e201-14
pubmed: 26805586
AJP Rep. 2020 Jan;10(1):e78-e86
pubmed: 32158618
Lancet Glob Health. 2020 Aug;8(8):e1071-e1080
pubmed: 32710863
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
BMJ Open. 2021 Nov 23;11(11):e053288
pubmed: 34815287
BMC Health Serv Res. 2018 Dec 20;18(1):989
pubmed: 30572887
Int J Behav Med. 2020 Feb;27(1):3-20
pubmed: 32060805
BMC Med Ethics. 2019 Nov 14;20(1):82
pubmed: 31727044
Am J Clin Nutr. 2000 May;71(5 Suppl):1280S-4S
pubmed: 10799402
Nutrients. 2018 Sep 10;10(9):
pubmed: 30201880
Cochrane Database Syst Rev. 2016 Apr 18;4:CD009747
pubmed: 27087396
J R Soc Med. 2011 Dec;104(12):510-20
pubmed: 22179294
Aust N Z J Obstet Gynaecol. 2018 Feb;58(1):22-39
pubmed: 28921558
J Obstet Gynaecol India. 2015 Jul;65(4):230-5
pubmed: 26243988
Aust N Z J Obstet Gynaecol. 2016 Apr;56(2):162-72
pubmed: 26537197
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
BMC Pregnancy Childbirth. 2020 Nov 4;20(1):665
pubmed: 33148203
J Perinatol. 2019 Apr;39(4):519-532
pubmed: 30692612
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Lancet Glob Health. 2013 Jul;1(1):e16-25
pubmed: 25103581
BMJ. 2017 Mar 6;356:i6795
pubmed: 28264797
J Gen Intern Med. 2006 Feb;21 Suppl 2:S1-8
pubmed: 16637954
Front Public Health. 2020 Mar 03;8:59
pubmed: 32195217
Pediatr Ann. 1998 Sep;27(9):581-4
pubmed: 9778710
Int J Equity Health. 2013 Mar 11;12:18
pubmed: 23496984
Annu Rev Public Health. 2009;30:151-74
pubmed: 19705558
Blood. 2017 Feb 23;129(8):940-949
pubmed: 28034892
N Engl J Med. 2021 Sep 9;385(11):982-995
pubmed: 34496174
Health Promot Int. 2006 Mar;21(1):76-83
pubmed: 16249192
Implement Sci. 2019 Dec 5;14(1):102
pubmed: 31806037
Lancet. 2006 Apr 1;367(9516):1066-1074
pubmed: 16581405
Curr Dev Nutr. 2019 Oct 21;3(12):nzz120
pubmed: 31777771
Acad Med. 2014 Sep;89(9):1245-51
pubmed: 24979285

Auteurs

Khic-Houy Prang (KH)

Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.

Elisabeth Mamani-Mategula (E)

Kamuzu University of Health Sciences, Blantyre, Malawi.

Ebony Verbunt (E)

Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.

Effie Chipeta (E)

Kamuzu University of Health Sciences, Blantyre, Malawi.

Ricardo Ataide (R)

Population Health and Immunity division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
Department of Infectious Diseases, Peter Doherty Institute, University of Melbourne, Melbourne, Australia.

Martin Mwangi (M)

Kamuzu University of Health Sciences, Blantyre, Malawi.

Kamija Phiri (K)

Kamuzu University of Health Sciences, Blantyre, Malawi.

Sant-Rayn Pasricha (SR)

Population Health and Immunity division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.

Margaret Kelaher (M)

Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.

Lucinda Manda-Taylor (L)

Kamuzu University of Health Sciences, Blantyre, Malawi. mandal@kuhes.ac.mw.

Classifications MeSH